Evidence map›Paper›PMID 24351043›Full record

ArticleAssay and drug development technologies

Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.

David Paul Jenkins, Weifeng Yu, Brandon M Brown, Lars Damgaard Løjkner, Heike Wulff

Abstract read
In one paragraph

Article in Assay and drug development technologies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Extracellular KBioelectricity · 2019
    Article
  6. Article
  7. Impact of Aging on Calcium Signaling and Membrane Potential in Endothelium of Resistance Arteries: A Role for Mitochondria.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

David Paul Jenkins1 Department of Pharmacology, University of California , Davis, California.
Weifeng Yu
Brandon M Brown
Lars Damgaard Løjkner
Heike Wulff

Funding

Training and Education CoreU54NS079202 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEIN, PAMELA J · 2012 to 2021
$35.7M
Training Program in Biomolecular TechnologyT32GM008799 · NIGMS · UNIVERSITY OF CALIFORNIA DAVIS · PI LEACH, J. KENT · 2002 to 2016
$2.4M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
Optimization of KCa2 Channel Activators as Neuroscience Tools and Potential DrugsR21NS072585 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WULFF, HEIKE · 2011 to 2012
$440k
NIGMS NIH HHS T32-GM008799NIGMS NIH HHS T32 GM099608NINDS NIH HHS R21NS072585NINDS NIH HHS U54NS079202
6 · The paper itself

Abstract

The intermediate-conductance Ca(2+)-activated K(+) channel KCa3.1 (also known as KCNN4, IK1, or the Gárdos channel) plays an important role in the activation of T and B cells, mast cells, macrophages, and microglia by regulating membrane potential, cellular volume, and calcium signaling. KCa3.1 is further involved in the proliferation of dedifferentiated vascular smooth muscle cells and fibroblast and endothelium-derived hyperpolarization responses in the vascular endothelium. Accordingly, KCa3.1 inhibitors are therapeutically interesting as immunosuppressants and for the treatment of a wide range of fibroproliferative disorders, whereas KCa3.1 activators constitute a potential new class of endothelial function preserving antihypertensives. Here, we report the development of QPatch assays for both KCa3.1 inhibitors and activators. During assay optimization, the Ca(2+) sensitivity of KCa3.1 was studied using varying intracellular Ca(2+) concentrations. A free Ca(2+) concentration of 1 μM was chosen to optimally test inhibitors. To identify activators, which generally act as positive gating modulators, a lower Ca(2+) concentration (∼200 nM) was used. The QPatch results were benchmarked against manual patch-clamp electrophysiology by determining the potency of several commonly used KCa3.1 inhibitors (TRAM-34, NS6180, ChTX) and activators (EBIO, riluzole, SKA-31). Collectively, our results demonstrate that the QPatch provides a comparable but much faster approach to study compound interactions with KCa3.1 channels in a robust and reliable assay.

Indexed as

Biological AssayDrug Evaluation, PreclinicalFlow CytometryFlow Injection AnalysisHEK293 CellsHumansIntermediate-Conductance Calcium-Activated Potassium ChannelsIon Channel GatingMembrane PotentialsPatch-Clamp TechniquesPotassium Channel BlockersRoboticsIntermediate-Conductance Calcium-Activated Potassium ChannelsKCNN4 protein, humanPotassium Channel Blockers

Identifiers

PMID24351043
PMCPMC3870577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.